High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Financial Disclosure Prof. Menon has stock ownership and has received research funding
from Abcodia Ltd, a UCL spinout company with an interest in biomarkers and commercial …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic provide recommendations for genetic testing and counseling for hereditary …

Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes
(BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and …

Purpose Deleterious germline mutations contribute to pancreatic cancer susceptibility and
are well documented in families in which multiple members have had pancreatic cancer …

Nearly 3% of the population carries genetic variants that lead to conditions that include
hereditary breast and ovarian cancer and Lynch syndrome. These pathogenic variants …

Background The cost-effectiveness of population-based panel testing for high-and moderate-
penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We …

Homologous recombination and DNA repair are important for genome maintenance.
Genetic variations in essential homologous recombination genes, including BRCA1 and …

Background The presence of deleterious mutations in breast cancer 1 gene (BRCA1) or
breast cancer 2 gene (BRCA2) significantly increases the risk of developing some cancers …

Pancreatic cancer remains a leading cause of cancer-related death with few available
therapies for advanced disease. Recently, patients with germline BRCA mutations have …